Eton Pharmaceuticals Inc (ETON)

Currency in USD
26.970
-0.150(-0.55%)
Closed·
26.594-0.376(-1.40%)
·
Trading near 52-week High
ETON is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.79627.285
52 wk Range
13.08527.285
Key Statistics
Prev. Close
27.12
Open
27.1
Day's Range
26.796-27.285
52 wk Range
13.085-27.285
Volume
347.78K
Average Vol. (3m)
349.26K
1-Year Change
90.0634%
Book Value / Share
0.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ETON Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.333
Upside
+45.84%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Eton Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Employees
44

Eton Pharmaceuticals Inc Earnings Call Summary for Q4/2025

  • Eton Pharmaceuticals Q4 2025 EPS of $0.19 beat estimates by 5.56%; revenue of $21.3M missed forecasts by 3.01%, stock surged 9.2% to $19.02.
  • Revenue jumped 83% year-over-year driven by successful product launches and acquisitions; adjusted EBITDA margin improved to 29% from 18%.
  • Company swung to GAAP net income of $1.5M from $0.6M loss in Q4 2024, demonstrating strong profitability turnaround.
  • Management expects continued EPS and revenue growth through new product launches and strategic acquisitions to enhance market penetration.
  • Key risks include supply chain disruptions, rising R&D/G&A expenses, market saturation, and regulatory approval challenges.
Last Updated: 03/19/2026, 05:49 PM
Read Full Transcript

Compare ETON to Peers and Sector

Metrics to compare
ETON
Peers
Sector
Relationship
P/E Ratio
−159.9x−5.8x−0.5x
PEG Ratio
10.100.110.00
Price / Book
28.1x0.7x2.6x
Price / LTM Sales
9.2x1.5x3.2x
Upside (Analyst Target)
29.9%109.6%47.6%
Fair Value Upside
Unlock12.5%6.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 39.333
(+45.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy52.00+92.81%37.00MaintainMar 23, 2026
H.C. Wainwright
Buy52.00+92.81%37.00MaintainMar 20, 2026
Craig-Hallum
Buy35.00+29.77%30.00MaintainMar 20, 2026
B.Riley
Buy31.00+14.94%26.00MaintainMar 20, 2026
Craig-Hallum
Buy30.00+11.23%29.00MaintainMar 03, 2026

Earnings

Latest Release
Mar 19, 2026
EPS / Forecast
0.19 / 0.18
Revenue / Forecast
21.3M / 21.96M
EPS Revisions
Last 90 days

ETON Income Statement

People Also Watch

52.710
TERN
+0.06%
3.30
BATL
-1.49%
142.520
AAOI
-2.64%
34.410
PL
+1.41%

FAQ

What Is the Eton Pharmaceuticals (ETON) Stock Price Today?

The Eton Pharmaceuticals stock price today is 26.970 USD.

What Stock Exchange Does Eton Pharmaceuticals Trade On?

Eton Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Eton Pharmaceuticals?

The stock symbol for Eton Pharmaceuticals is "ETON."

What Is the Eton Pharmaceuticals Market Cap?

As of today, Eton Pharmaceuticals market cap is 734.360M USD.

What Is Eton Pharmaceuticals's Earnings Per Share (TTM)?

The Eton Pharmaceuticals EPS (TTM) is -0.171.

When Is the Next Eton Pharmaceuticals Earnings Date?

Eton Pharmaceuticals will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is ETON a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Eton Pharmaceuticals Stock Split?

Eton Pharmaceuticals has split 0 times.

How Many Employees Does Eton Pharmaceuticals Have?

Eton Pharmaceuticals has 44 employees.

What is the current trading status of Eton Pharmaceuticals (ETON)?

As of Apr 15, 2026, Eton Pharmaceuticals (ETON) is trading at a price of 26.970 USD, with a previous close of 27.120 USD. The stock has fluctuated within a day range of 26.796 USD to 27.285 USD, while its 52-week range spans from 13.085 USD to 27.285 USD.

What Is Eton Pharmaceuticals (ETON) Price Target According to Analysts?

The average 12-month price target for Eton Pharmaceuticals is 39.333 USD, with a high estimate of 52 USD and a low estimate of 31 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +45.84% Upside potential.

What Is the ETON Premarket Price?

ETON's last pre-market stock price is 27.340 USD. The pre-market share volume is 30.000, and the stock has decreased by 0.220, or 0.810%.

What Is the ETON After Hours Price?

ETON's last after hours stock price is 26.594 USD, the stock has decreased by -0.376, or -1.400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.